首页> 美国卫生研究院文献>Springer Open Choice >Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies
【2h】

Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies

机译:人为因素工程(HFE)在纳洛酮自动注射器设计中的应用(用于治疗阿片类药物紧急情况)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The increased use of opioids for chronic treatment of pain and the resulting epidemic of opioid overdoses have created a major public health challenge. Parenteral naloxone has been used since the 1970’s to treat opioid overdose. Recently, a novel naloxone auto-injector device (EVZIO, kaleo, Inc., Richmond, VA) was approved by the Food and Drug Administration. In this article, we review the Human Factors Engineering (HFE) process used in the development and testing of this novel naloxone auto-injector currently used in nonmedical settings for the emergency treatment of known or suspected opioid overdose. HFE methods were employed throughout the product development process for the naloxone auto-injector including formative and summative studies in order to optimize the auto-injector’s user interface, mitigate use-related hazards and increase reliability during an opioid emergency use scenario. HFE was also used to optimize the product’s design and user interface in order to reduce or prevent user confusion and misuse. The naloxone auto-injector went through a rigorous HFE process that included perceptual, cognitive, and physical action analysis; formative usability evaluations; use error analysis and summative design validation studies. Applying HFE resulted in the development of a product that is safe, fast, easy and predictably reliable to deliver a potentially life-saving dose of naloxone during an opioid overdose emergency. The naloxone auto-injector may be considered as a universal precaution option for at-risk patients prescribed opioids or those who are at increased risk for an opioid overdose emergency.
机译:阿片类药物在慢性疼痛治疗中的使用增加,以及由此产生的阿片类药物过量的流行,给公共卫生带来了重大挑战。自1970年代以来,肠胃外纳洛酮已用于治疗阿片类药物过量。最近,一种新型的纳洛酮自动注射器装置(EVZIO,kaleo,Inc。,弗吉尼亚州里士满)被食品药品监督管理局批准。在本文中,我们回顾了开发和测试这种新型纳洛酮自动注射器的人为因素工程(HFE)工艺,该纳洛酮自动注射器目前在非医疗环境中用于紧急治疗已知或可疑的阿片类药物过量。在纳洛酮自动注射器的整个产品开发过程中都采用了HFE方法,包括形成性研究和总结性研究,以优化自动注射器的用户界面,减轻与阿片类药物有关的危害并提高阿片类药物紧急使用场景下的可靠性。 HFE还用于优化产品的设计和用户界面,以减少或防止用户混淆和误用。纳洛酮自动注射器经过了严格的HFE过程,包括知觉,认知和身体动作分析。形成性可用性评估;使用错误分析和汇总设计验证研究。应用HFE导致开发出一种安全,快速,简便且可预测地可靠的产品,可在阿片类药物过量紧急情况下提供可能挽救生命的纳洛酮剂量。对于开处方阿片类药物的高危患者或发生阿片类药物过量紧急情况风险较高的患者,可以将纳洛酮自动注射器视为一种普遍的预防措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号